soul trial oral semaglutide cardiovascular outcomes soul trial results The Study SOUL (Semaglutide cardiOvascular oUtcomes triaL)

GLP-1 medications have recently gained traction due to their ability to regulate blood sugar levels and promote weight loss

From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg ( n = 152) or placebo ( n = 152), 92.8% of whom completed the trial (attended the end-of-trial safety visit)

The treatments progress showed 54.9% achieved a weight reduction of 10% or more, 23.5% reached 15% or more, and 7.8% accomplished an exceptional 20% or more weight loss

Total-cost math over 72 weeks: LillyDirect vials of tirzepatide around $5,000

The final matching used 27 characteristics for the T2D groups and 26 characteristics for the T2D plus ASCVD groups (see online Supplementary Methods)

This quick impact is because semaglutide communicates directly with your brains hunger centers, signaling satiety even with smaller meals